P-glycoprotein associated with diabetes mellitus and survival of patients with pancreatic cancer: 8-year follow-up

Nan Hu*, Hui Wang*, Qing Qian, Yan Jiang, Jun Xie, Dachuan Zhang, Qing Li, Sulan Zou, and Rong Chen

1Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
2Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Abstract

Diabetes mellitus (DM) has a high prevalence in patients with pancreatic cancer (PaC), but the prognostic value of DM in PaC remains controversial. Alterations of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) contribute to multidrug resistance and intestinal metabolism in a variety of cancer types, which may be implicated in DM development. This study aimed to explore the potential prognostic value of P-gp and CYP3A4 in PaC patients in the context of DM through long-term follow-up. We retrospectively reviewed the medical records of patients with PaC admitted at The First People’s Hospital of Changzhou, Jiangsu, China, from January 2011 to November 2019 and identified two cohorts of adult patients with PaC, including 24 with DM and 24 without DM (non-DM). The baseline clinical characteristics and outcomes were compared. Immunohistochemistry showed that protein expression of P-gp, but not CYP3A, in duodenum tissues was significantly upregulated in PaC patients with DM compared with those without DM. Kaplan-Meier analysis and log-rank test showed that the survival of patients with PaC and DM/high expression of P-gp was not significantly reduced compared with that of patients without DM/low expression of P-gp. These findings suggested that P-gp expression levels were different in the DM and non-DM groups of patients with PaC, but DM and duodenal P-gp levels were not associated with the long-term survival of patients with PaC. It appears that the presence of DM or P-gp expression levels may not serve as effective prognostic markers for PaC.

Key words: Cohort study; Cytochrome P450 3A4; P-glycoprotein; Pancreatic cancer with diabetes mellitus

Introduction

According to GLOBOCAN 2018, pancreatic cancer (PaC) is the 11th most common cancer, estimated to have caused 432,242 deaths in 2018 (1). Currently, available treatment options for PaC are surgical resection, chemotherapy, and radiotherapy (2), among which surgical resection is considered the mainstay of curative treatment and is associated with better long-term survival (3). Nevertheless, 80–90% of patients with PaC are diagnosed at an advanced stage and with unresectable tumors, and the 5-year survival rate of PaC is as low as 5% (4). Identification of poor prognostic factors in PaC may provide valuable prognostic information for selecting appropriate treatment protocols. Although factors like tumor stage, grading, lymph node ratio, surgical margin, and tumor size have been identified as prognostic factors in PaC (5,6), it is of great importance to identify new biological or pathological indicators related to the survival of patients with PaC.

Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia resulting from insufficient insulin secretion, resistance to insulin action, or both (7), posing an increasingly serious threat to human health worldwide with an estimated global prevalence of 592 million by 2035 (8). DM is known as a possible risk factor and/or an early manifestation of PaC, being concurrently present in 50–80% of patients with PaC (9,10). Accumulating evidence suggests that concurrent diagnosis of DM is associated with increased risk of cancer recurrence and mortality in patients with colorectal, breast, liver, endometrial, and gastric cancers as well as leukemia (11). Nevertheless, how DM affects the clinical outcome and survival of patients with PaC remains controversial. Some studies
reported that the presence of DM does not have a statistically significant effect on the overall survival (OS) or the mortality of PaC (11,12), whereas others found a significant association between DM and reduced survival in PaC (13). Therefore, the characterization of a reliable indicator related to survival and clinical outcome is required for predicting prognosis and selecting appropriate therapeutic strategies for patients with PaC and DM.

Systemic chemotherapy is used for advanced PaC after surgery or unresectable metastatic PaC, which significantly extends OS and improves patient outcome (14). Intrinsic or acquired resistance to chemotherapy remains the major cause of treatment failure (15). The drug efflux protein P-glycoprotein (P-gp) and drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) are both expressed in the intestinal mucosa and serve as barriers to oral drug delivery by regulating pharmacokinetic and pharmacodynamic interactions during the process of drug absorption and metabolism (16,17). P-gp and CYP3A4 are overexpressed in a number of different cancers such as ovarian, breast, and colon cancers, and some studies showed that they are associated with resistance to therapy and/or poor prognosis (18,19). In patients with coexisting PaC and DM, alterations of P-gp and CYP3A4 may become more complicated due to the hyperglycemic environment and diabetes medications (20). A recent study showed that the expression of intestinal P-gp was significantly increased with the progression of diabetes in rats (induced by low dose streptozotocin and high-fat diet), resulting in a significant decrease in the intestinal uptake and peroral bioavailability of the P-gp/CYP substrates verapamil and atorvastatin (21). Peroral bioavailability of drugs is a primary concern for patients with coexisting PaC and DM who are usually prescribed with multiple drugs for effective management of blood glucose levels and cancer progression. Little is known with respect to the expression patterns of intestinal P-gp and CYP3A4 in PaC patients in the context of DM, as well as their correlation with patient prognosis.

In the present study, we retrospectively reviewed the records of patients with PaC admitted to The First People’s Hospital of Changzhou, Jiangsu, China from January 2011 to November 2019, we identified 24 consecutive adult patients with pathologically confirmed PaC and DM. Another cohort of unmatched 24 patients with PaC but without DM (non-DM) was randomly selected from the database. The patients with other cancers, undergoing radiotherapy/chemotherapy, with incomplete data, or lost to follow-up were excluded. The patient characteristics are described in Table 1. This study was approved by the Ethics Committee of The First People’s Hospital of Changzhou. Informed consent was obtained from each patient.

Immunohistochemistry (IHC)

IHC was performed using the Elivision™ method (Maixin-Bio, Fuzhou, China). Duodenum tissue samples were obtained during surgery and fixed in 4% formalin. Paraffin-embedded tissue sections (3–4-μm thick) were prepared. The sections were dewaxed in xylene and dehydrated in ethanol, followed by incubation with 3% H2O2 for 15 min. After additional incubation with 10% normal bovine serum for 10 min, each slide was incubated with primary antibodies against human P-gp (MAB-0237, MXB Biotechnologies, China) or CYP3A4 (ab3572, Abcam, UK) at 4°C overnight. The protein expression was visualized using an ultraView universal DAB detection kit (Ventana, Roche, USA). The positive and negative controls were provided by the manufacturer. The results were blindly scored (0–100%) by two independent pathologists using an Olympus IX73 microscope (Olympus Corp., Japan) and the following algorithm: [(3 × intensity of specific immunodetection) + (2 × amount of immunodetected structures) + (2 × intensity of non-specific immunodetection) + (1 × intensity of contrast) + (1 × preservation of morphology)] × 3703 (constant that allows conversion to the 0–100 score), as previously described (22). Five randomly selected fields were scored in each slide. The final score is reported as the average of the scores of two pathologists. A reassessment was performed when the deviation was ≥20%.

Statistical analysis

Statistical analyses were carried out using the SPSS software (version 19.0; IBM, USA). Data are reported as median (range). Comparison between two groups was conducted using the chi-squared test or unpaired Student’s t-test. Differences between categorical variables were compared using the chi-squared test. The survival of patients with PaC was assessed using Kaplan-Meier analysis and the log-rank test. A value of P<0.05 was considered statistically significant.

Results

Comparison of clinicopathological characteristics between patients with PaC with/without DM

To identify the possible features of DM in patients with PaC, we compared the clinicopathologic characteristics of patients with PaC with/without DM. In the DM group, the

Material and Methods

Patients

From the database of patients at The First People’s Hospital of Changzhou, Jiangsu, China, from January 2011 to November 2019, we identified 24 consecutive adult patients with pathologically confirmed PaC and DM. Another cohort of unmatched 24 patients with PaC but without DM (non-DM) was randomly selected from the database. The patients with other cancers, undergoing radiotherapy/chemotherapy, with incomplete data, or lost to follow-up were excluded. The patient characteristics are described in Table 1. This study was approved by the Ethics Committee of The First People’s Hospital of Changzhou. Informed consent was obtained from each patient.
Table 1. Clinicopathological characteristics of patients with pancreatic cancer with or without diabetes mellitus (DM).

| Clinicopathological variables | DM (n=24) | Non-DM (n=24) | P     |
|-------------------------------|-----------|---------------|-------|
| Sex                           |           |               | 0.019 |
| Male                          | 10 (41.7%)| 18 (75.0%)    |       |
| Female                        | 14 (58.3%)| 6 (25.0%)     |       |
| Age                           | 67.50 (43.00, 83.00) | 65.00 (48.00, 82.00) | 0.297 |
| Weight (kg)                   | 59.00 (45.00, 78.00) | 62.00 (46.00, 89.00) | 0.260 |
| Height (cm)                   | 181.50 (152.00, 175.00) | 166.50 (156.00, 177.00) | 0.032 |
| Smoking/alcohol               | 1 (4.3%)  | 3 (12.5%)     | 0.317 |
| Hypertension*                 | 9 (37.5%) | 9 (37.5%)     | 1.000 |
| Duration of DM (years)        | 3.00 (0.10, 30.00) | -             | N/A   |
| Medications                   | N/A       |               |       |
| N/A                           | 2 (11.8%) | -             |       |
| Gliclazide                    | 1 (5.9%)  | -             |       |
| Metformin                     | 1 (5.9%)  | -             |       |
| Metformin + repaglinide       | 2 (11.8%) | -             |       |
| Metformin + insulin           | 1 (5.9%)  | -             |       |
| Repaglinide                   | 2 (11.8%) | -             |       |
| Insulin                       | 8 (47.1%) | -             |       |
| Fasting blood glucose (mM)    | 7.95 (3.80, 12.50) | 5.70 (3.90, 12.30) | 0.001 |
| Postprandial blood glucose (2 h, mM) | 14.90 (6.90, 28.50) | - | N/A |
| WBC count (× 10^9)            | 5.86 (3.99, 11.30) | 5.27 (3.07, 10.75) | 0.068 |
| RBC count (× 10^12 )          | 3.94 (2.70, 5.18)  | 4.36 (2.41, 5.41) | 0.155 |
| Hemoglobin (g/L)              | 124.50 (86.00, 160.00) | 132.50 (65.00, 149.00) | 0.458 |
| ALT (U/L, median, range)      | 151.50 (7.00, 339.00) | 68.00 (11.00, 950.00) | 0.773 |
| AST (U/L, median, range)      | 62.00 (7.00, 259.00) | 53.50 (13.00, 883.00) | 0.695 |
| Potassium (mM)                | 4.26 (2.70, 5.66)  | 4.25 (3.36, 5.55) | 0.643 |
| Sodium (mM)                   | 138.10 (132.00, 143.90) | 141.15 (135.90, 147.50) | 0.030 |
| Chloride (mM)                 | 98.35 (92.00, 106.10) | 99.60 (93.70, 107.70) | 0.143 |
| Albumin (g/L)                 | 35.35 (28.30, 47.50) | 32.40 (22.70, 42.60) | 0.101 |
| BUN (mM)                      | 4.24 (2.37, 7.29)  | 4.32 (1.47, 6.57) | 0.386 |
| Creatinine (µM)               | 71.65 (39.90, 93.00) | 63.50 (37.00, 118.20) | 0.115 |
| Total cholesterol (mM)        | 5.32 (2.80, 8.88)  | 4.08 (2.34, 6.00) | 0.002 |
| Triglycerides (mM)            | 2.28 (0.51, 9.38)  | 1.69 (0.62, 4.32) | 0.334 |
| HDL (mM)                      | 0.92 (0.42, 3.01)  | 0.96 (0.17, 2.04) | 0.599 |
| LDL (mM)                      | 2.41 (0.91, 4.30)  | 1.97 (0.36, 2.68) | 0.045 |
| Tumor stage                   | 5 (45.8%)    | 18 (75.0%)    | >0.99 |
| I                             | 4 (16.6%)    | 2 (8.3%)      |       |
| II                            | 16 (66.7%)   | 19 (79.2%)    |       |
| III                           | 4 (16.7%)    | 3 (12.5%)     |       |
| ECOG                          | 0.855        |               |       |
| 0                             | 5 (20.8%)    | 7 (29.2%)     |       |
| 1                             | 14 (58.4%)   | 13 (54.2%)    |       |
| 2                             | 5 (20.8%)    | 4 (16.6%)     |       |
| Radiotherapy                  | 2            | 1             | >0.99 |
| Chemotherapy                  |              |               |       |
| Gemcitabine + capecitabine    | 1            | 3             | 0.609 |
| Gemcitabine + oxaliplatin     | 2            | 1             | >0.99 |
| Gemcitabine + TGOPC           | 2            | 1             | >0.99 |
| Capecitabine + irinotecan     | 1            | 0             | >0.99 |
| Gemcitabine                   | 3            | 2             | >0.99 |
| TGOPC                         | 0            | 1             | >0.99 |
| P-gp                          |              |               | <0.001|
| <85                           | 6 (25.0%)    | 18 (75.0%)    |       |
| ≥85                           | 18 (75.0%)   | 6 (25.0%)     |       |

Categorical data are reported as number (%) and continuous data as median (range) [chi-squared test (categorical) and Student’s t-test (continuous)]. *Defined as drug treatment for hypertension. N/A, not available; WBC, white blood cell; RBC: red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; ECOG: Eastern Cooperative Oncology Group; P-gp: P-glycoprotein; TGOPC: tegafur gimeracil oteracil potassium capsule."
The median duration of DM was 3.0 (range, 0.1–30.0) years. As shown in Table 1, the blood levels of fasting blood glucose (P=0.001), sodium (P=0.003), total cholesterol (P=0.002), and low-density lipoprotein cholesterol (P=0.045) were significantly higher in the DM group than in the non-DM group, suggesting dysregulated glucose and lipid metabolism in patients with PaC and DM. In addition, the DM group included more women (58.3 vs 25.0%, P=0.02), and the patients in the non-DM group were taller (P=0.03), without a difference in weight (P=0.26). There were no differences between the two groups regarding smoking, alcohol, other biochemical indicators, tumor stage, and Eastern Cooperative Oncology Group (ECOG) score (all P >0.05). The proportion of patients with a P-gp score ≥85 was higher in the DM group than in the non-DM group (75.0 vs 25.0%, P <0.001).

**P-gp, but not CYP3A4, was significantly upregulated in duodenal tissues of patients with PaC and DM**

Since P-gp and CYP3A4 are able to form an intestinal absorption barrier that is closely associated with multidrug resistance (17), we sought to investigate the possible association of P-gp and CYP3A4 expression with the presence of DM in patients with PaC. Based on the IHC results for these two proteins in duodenum tissue samples of patients with PaC with/without DM (Figure 1), the mean IHC score of duodenal P-gp in the DM group was significantly higher than that in the non-DM group (Table 2; Figure 2A–F), whereas the mean IHC score of duodenal CYP3A4 was not significantly different between the two groups (Table 2; Figure 3A–F).

**DM and duodenal P-gp levels were not associated with the OS of patients with PaC**

The OS of patients with PaC and DM or high expression of P-gp (IHC score >85) was not significantly lower compared with that of patients without DM or with low expression of P-gp (P=0.291 and P=0.958) (Figure 4). In addition, the multivariable Cox regression analysis showed that there was no association between other variables and survival in patients with PaC (data not shown). These data suggested that, at least in this cohort of patients, the presence of DM and high duodenal P-gp levels were not associated with the OS of patients with PaC.

![Figure 1](image_url). Hematoxylin and eosin staining of duodenum tissues from patients with pancreatic cancer with (A and B) or without (C and D) diabetes mellitus. Representative images are shown. Magnification 100 × (A and C, scale bar 100 μm) and 200 × (B and D, scale bar 50 μm).

|                  | DM (n=24)              | Non-DM (n=24)   | P        |
|------------------|------------------------|----------------|----------|
| P-gp             | 92.50 (20.00, 100.00)  | 65.00 (10.00, 95.00) | <0.001   |
| CYP3A4           | 80.00 (20.00, 100.00)  | 72.50 (0.00, 100.00) | 0.312    |

Data are reported as median (range) (Student’s t-test). CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein.
Cox analysis for death

The univariate and multivariate Cox analyses were conducted. Triglycerides (HR=0.777, 95%CI: 0.616–0.980, P=0.033) and ECOG=2 (HR=3.047, 95%CI: 1.098–8.459, P=0.032) were associated with mortality in the univariate analyses. In the multivariate analysis, no variable was associated with mortality.

Discussion

In the present study, we compared the protein levels of P-gp and CYP3A4 in duodenum tissues between patients with PaC with/without DM and found that P-gp, but not CYP3A4, was significantly upregulated in the DM group vs the non-DM group, suggesting a possible positive correlation between duodenal expression of P-gp and the presence of DM in patients with PaC. Despite the negative results of the association analyses of patient survival with DM and duodenal P-gp levels, our findings may provide new clues for a better understanding of the chemoresistance-related genetic alterations in PaC in the context of DM.

P-gp protein expression was different in the DM and non-DM groups, suggesting that the expression of the P-gp protein was affected by DM and that drug resistance might theoretically be different. Although P-gp was first identified in drug-resistant cancer cells, it is also expressed in a wide variety of normal tissues (small intestine, liver, and kidney) as well as in blood-tissue barriers (23), serving as an efflux transporter against the entry of toxic xenobiotics, such as therapeutic drugs, dietary compounds, and environmental toxins, into the tissues (24). Previous studies suggest that the expression of P-gp changes in various pathological conditions at different tissue levels (25,26). With reference to DM, Yeh et al. (25) reported that hyperglycemia suppresses renal P-gp expression in rats, whereas another group has observed the overexpression of P-gp in the blood-brain barrier of streptozotocin-induced diabetic rats (27). As peroral bioavailability of drugs will be primarily affected by intestinal P-gp and patients with PaC and DM are usually prescribed multiple medications, it is of great importance to evaluate the intestinal P-gp expression in these patients. In this study, the upregulation of duodenal P-gp expression in patients with PaC and DM was higher.
than that in patients with PaC but without DM, which was consistent with a recent study showing that intestinal P-gp can be significantly increased along with the progression of DM in rats (21). As an ATP-mediated transporter, the ATPase enzyme is required for the function of P-gp (28), but we did not measure the ATPase activity in this retrospective cohort study, which should be addressed in the future.

Elevated expression of P-gp in response to chemotherapy has been reported in different malignancies, and P-gp was first identified in chemotherapy-resistant cancer cells. For example, a dramatic increase in P-gp expression from 15 to 43% was observed in breast tumor biopsies following treatment with conventional chemotherapy (29). Likewise, in a multiple myeloma study, P-gp expression was 6% at diagnosis, which increased to 43% after treatment (30). In addition, the expression of P-gp is associated with the survival of patients with cancer. Indeed, a shorter OS in patients with acute myelogenous leukemia was associated with upregulated P-gp expression (31). Similarly, patients with PaC and high P-gp expression in PaC tissues have shorter survival compared with those with weak or moderate expression of P-gp (32).

Paradoxically, in the same report, it was also observed that the survival of patients with high expression of P-gp was not significantly different from that of those without detectable P-gp expression (32).

Therefore, based on the association between duodenal P-gp levels and DM in patients with PaC, we explored whether DM or duodenal P-gp expression could affect the survival of patients with PaC. We observed shorter survival in the DM and high P-gp expression groups compared with the non-DM and low P-gp expression groups, but the differences between the groups were not significant, possibly due to the small sample size of this study and the impossibility of adjusting for confounding factors. Furthermore, most of the patients in this study were treated with metformin, the first-line drug for type-2 diabetes (33). In addition to its hypoglycemic effects, metformin has been shown to inhibit chemotherapy resistance in a variety of solid tumors, including PaC (34–36). The mechanisms include decreased microvessel density, leakage, and hypoxia (34), enhancement of the effects of anti-proliferation drugs (35), and inhibition of chemoresistance (36). Those effects could improve the survival of the patients and might have contributed to the lack of a significant difference between the DM and non-DM groups in the present study. Indeed, metformin is associated with improved survival in patients with solid tumors (37–40). Future studies should seek to include patients with PaC and DM but without treatment for DM with metformin.

The primary limitation of the present study is that it had a small sample size from a single center. In addition, it was a retrospective cohort study, resulting in selection biases. The data that could be analyzed were limited to those available from the medical charts. Furthermore, based on the available data, it was impossible to determine the causal relationship between DM and PaC with any certitude. Thus, the prognostic value of DM and P-gp in PaC remains disputable (11–13), and a larger sample size may be required for further confirmation of the results of the present study.

In conclusion, our study showed that the protein levels of duodenal P-gp were significantly elevated in PaC patients with DM compared with those without DM. Although there was no significant difference between patient survival and DM or P-gp levels, our results may still be helpful for a better understanding of drug resistance-related gene dysregulation in PaC patients.

**Acknowledgments**

This study was funded by the National Science Foundation of China (No. 81503136), the Changzhou High-Level Medical Talents Training Project (No. 2016CZBJ010), the Changzhou Science and Technology Project (Applied Based Research No. 2016404), and the Jiangsu Pharmaceutical Association-Aosaikang Clinical Pharmacy Foundation (No. A201920).
References

1. Bray F, Fertay J, Sorojmataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424, doi: 10.3322/caac.21492.

2. Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Liu Y, et al. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014; 120: 499–506, doi: 10.1002/cncr.28530.

3. Kang SP, Saif MW. Clinical outcome of pancreatic cancer with diabetes mellitus. Digestive & Liver Disease 2011; 43: 89–97, doi: 10.1016/j.dld.2010.07.010.

4. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Andren-Sandberg A. Prognostic factors in pancreatic adenocarcinoma: future directions for improving outcomes. Pancreatology 2015; 15: 8–18, doi: 10.1016/j.pan.2014.10.001.

5. Anderson-Sandberg A. Prognostic factors in pancreatic cancer. N Am J Med Sci 2012; 4: 9–12, doi: 10.4103/1947-2714.92893.

6. Valsangkar NP, Bush DM, Michaelson JS, Ferrone CR, Wargo JA, Lillemoe KD, et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2014; 18: 257–266, doi: 10.1007/s11605-012-1974-7.

7. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32: S62–S67, doi: 10.2337/dc09-S062.

8. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137–149, doi: 10.1016/j.diabres.2013.11.002.

9. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928–1937, doi: 10.1016/j.ejca.2011.03.003.

10. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189–197, doi: 10.1007/s10552-010-9686-3.

11. Barone BB, Yeh HC, Snyder CF, Pears KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300: 2754–2764, doi: 10.1001/jama.2008.824.

12. Kim TD, Oh HJ, Kim KH, Kim SM, Kim JH, Sang BI, et al. Clinical characteristics of pancreatic cancer according to the presence of diabetes mellitus [in Korean]. Korean J Gastroenterol 2004; 43: 35–40, doi: 10.4166/kjg.2012.59.1.35.

13. Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the “2010 ASCO Annual Meeting”. Chicagol, IL, USA. June 4–8, 2010. JOP 2010; 11: 334–335, doi: 10.6092/1590-8577/3617.

14. Lee HS, Park SW. Systemic chemotherapy in advanced pancreatic cancer. Gut Liver 2016; 10: 340–347, doi: 10.5009/gnl15465.

15. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Desmoplasia and chemoresistance in pancreatic cancer. In: Grippo PJ, Munshi HG, editors. Pancreatic Cancer and Tumor Microenvironment. Trivandrum (India) 2012.

16. Eeang VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48: 543–552, doi: 10.1046/j.1365-2125.1999.00052.x.

17. Pal D, Kwatra D, Minocha M, Paturi DK, Buuda B, Mitra AK. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci 2011; 88: 959–971, doi: 10.1016/j.lfs.2010.09.012.

18. Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 2009; 21: 492–502, doi: 10.1158/1535-7163.MCT-11-1167.

19. Floriano-Sanchez E, Rodriguez NC, Bandala C, Coballase-Urrutia E, Lopez-Cruz J. CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev 2014; 15: 3805–3809, doi: 10.7314/APJCP.2014.15.8.3805.

20. May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab 2016; 7: 69–83, doi: 10.1177/2042188163608050.

21. Dash RP, Ellendula B, Agarwal M, Nivsarkar M. Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies. Eur J Pharmacol 2015; 767: 67–76, doi: 10.1016/j.ejphar.2015.10.009.

22. Borges-Ferro A, Santos AB, Filipe JL. Immunohistochemistry of formalin-gel fixed tissues. J Histotechnol 2014; 37: 48–53, doi: 10.1179/204623614X10000000040.

23. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423–429, doi: 10.1016/j.tips.2004.06.002.

24. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802–832, doi: 10.1080/00498250701867889.

25. Yeh SY, Pan HJ, Lin CC, Kao YH, Chen YH, Lin CJ. Hyperglycemia induced down-regulation of renal P-glycoprotein expression. Eur J Pharmacol 2012; 690: 42–50, doi: 10.1016/j.ejphar.2012.06.013.

26. Waghay D, Zhang Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. J Med Chem 2018; 61: 5108–5121, doi: 10.1021/acs.jmedchem.7b01457.

27. Maeng HJ, Kim MH, Jin HE, Shin SM, Tsuruo T, Kim SG, et al. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 2007; 35: 1996–2005, doi: 10.1124/dmd.107.015800.

28. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective
from bioavailability enhancement. Pharmacol Res 2003; 48: 347–359, doi: 10.1016/S1043-6618(03)00158-0.

29. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelena H, et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996; 77: 292–300, doi: 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X.

30. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–495, doi: 10.1182/blood.V81.2.490.

31. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661–1666.

32. Lu Z, Kleeff J, Shrikhande S, Zimmermann T, Korc M, Friess H, et al. Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 2000; 21: 240–247, doi: 10.1097/00006676-200010000-00004.

33. Introduction: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S1–S2, doi: 10.2337/dc20-Sint.

34. Wang JC, Li GY, Wang B, Han SX, Sun X, Jiang YN, et al. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. J Exp Clin Cancer Res 2019; 38: 235, doi: 10.1186/s13046-019-1211-2.

35. Candido S, Abrams SL, Steelman L, Lertpiriyapong K, Martelli AM, Cocco L, et al. Metformin influences drug sensitivity in pancreatic cancer cells. Adv Biol Regul 2018; 68: 13–30, doi: 10.1016/j.bior.2018.02.002.

36. Bai M, Yang L, Liao H, Liang X, Xie B, Xiong J, et al. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism. Oncogene 2018; 37: 5666–5681, doi: 10.1038/s41388-018-0360-7.

37. Zi F, Z H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An existing drug for cancer prevention and therapy. Oncol Lett 2018; 15: 683–690, doi: 10.3892/ol.2017.7412.

38. Sarai P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res 2019; 11: 3295–3313, doi: 10.2147/CMAR.S200059.

39. Yu H, Zhong X, Gao P, Shi J, Wu Z, Guo Z, et al. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne) 2019; 10: 617.

40. Lee DJ, McMullen CP, Foreman A, Huang SH, Lu L, Xu W, et al. Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study. J Otolaryngol Head Neck Surg 2019; 48: 34, doi: 10.1186/s40463-019-0348-5.